Colciago Riccardo Ray, De Santis Maria Carmen, Giandini Carlotta, Carnevale Maria Grazia, Di Cosimo Serena
School of Medicine and Surgery, University of Milan Bicocca, Milan, Italy.
Department of Radiation Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
Breast. 2025 Feb;79:103839. doi: 10.1016/j.breast.2024.103839. Epub 2024 Nov 14.
Up to 90 % of death from solid tumors are caused by metastases. By 2040, breast cancer (BC) is predicted to increase to over 3 million new cases. Additionally, with the personalization and intensification of BC follow-up, many patients will relapse with oligometastatic disease (OMD). Over the past decades, advances in treatment planning, image guidance, target position reproducibility, and online tracking, along with a compelling radiobiological rationale, have led to the implementation of Stereotactic Body Radiation Therapy (SBRT). This has become a valid ablative treatment option for OMD patients. However, there are still concerns about which patients benefit the most from ablative treatment. In this review, we will analyze the literature regarding SBRT for OMD in BC patients. We aim to present the current data on its effectiveness and define the optimal tailored scenarios for SBRT outcomes.
高达90%的实体瘤死亡是由转移引起的。预计到2040年，乳腺癌（BC）新发病例将增至300多万例。此外，随着乳腺癌随访的个性化和强化，许多患者会出现寡转移疾病（OMD）复发。在过去几十年中，治疗计划、图像引导、靶区位置可重复性和在线跟踪等方面的进展，以及令人信服的放射生物学理论依据，促使了立体定向体部放射治疗（SBRT）的实施。这已成为OMD患者一种有效的消融治疗选择。然而，对于哪些患者从消融治疗中获益最大仍存在担忧。在本综述中，我们将分析关于BC患者OMD的SBRT的文献。我们旨在展示其有效性的当前数据，并确定SBRT结果的最佳个性化方案。
